Inclusion Criteria:

• Age 50 or older
• Subject is able to sign informed consent
• Ability to complete 6 month trial
• Present with advanced AMD and persistently leaking CNV
• Adequate hematologic, renal and liver function
• Negative pregnancy test
• Subject is able to safely undertake all protocol directed instructions
• Visual acuity of 20/200 (logMAR 1.0)(6/60) or worse

Exclusion Criteria:

• Concomitant eye disease in eye to be treated
• Prior ocular radionuclide treatments
• Known allergic or hypersensitivity reactions to light and/or fluorescein and iodine or shellfish
• History of investigational drug or therapy including biologics within 30 days prior to the study drug dosing
• Women who are pregnant or lactating, or women of childbearing years not taking adequate contraception precautions
• History of porphyria, systemic lupus erythematosus, or xeroderma pigmentosum
• History of clinically significant cardiovascular abnormalities, including myocardial infarction in the past 6 months, uncontrolled arrhythmias, uncontrolled congestive heart failure
• Concomitant use of other drugs known to produce skin photosensitivity, e.g. tetracycline, sulfonamides, phenothiazines, sulfonylureas, thiazide diuretics and griseofulvin, St. John's Wort
• Subjects with high or pathological myopia with an axial length > 26mm or a refractive error of >/= -8.00D
• Subjects with glaucoma and vision loss in either eye
• Subject with a history of other choroidal leakage, e.g. histoplasmosis
• Subjects with significant media opacity
• Subjects diagnosed with diabetic retinopathy
• Subjects who have had eye surgery within the past 3 months
• Subjects who have received PDT treatment for AMD in the treatment eye
• Any disease or condition that the sponsor or the investigator believes will impact the subject's ability to adhere to the study schedule
• Subjects participating in any concurrent trial